Fact CheckerSign in

NCT06995599Not yet recruiting

Impact of Thoracic Duct Ligation on Postoperative Weight Reduction in Obese Patients Receiving Minimally Invasive Lung Surgery: A Clinical Investigation

Thoracic Duct Ligation and Postoperative Weight Loss in Obese Patients Undergoing Minimally Invasive Lung Surgery: A Pilot Exploratory Clinical Study

Source: ClinicalTrials.gov · Last updated 29 May 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This clinical trial aims to investigate whether thoracic duct ligation (TDL) can improve obesity and lipid metabolism. The primary questions it seeks to answer are: Whether thoracic duct ligation can improve BMI and lipid metabolism in obese patients. The safety and feasibility of thoracic duct ligation as a treatment for obesity.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
16 (estimated)
First submitted
2 Apr 2025
Start date
1 Jun 2025
Primary completion date
31 Dec 2027
Lead sponsor
Yongxin Zhou
Diseases
Obesity
NCT number
NCT06995599

What you commit to

  • Study type: Interventional
  • Planned participants: 16
  • From 1 Jun 2025 to the primary completion date, 31 Dec 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concurrent Thoracic Infections: Patients with active intrathoracic infectious diseases (e.g., inflammatory conditions, tuberculosis).
  • Prior Bariatric Surgery: History of weight-loss surgery (e.g., gastric bypass, sleeve gastrectomy).
  • Recent Trial Participation: Enrollment in other clinical trials within 30 days prior to screening.

Other illness

  • Clinically Unstable Comorbidities: Severe, unstable cardiovascular, renal, or respiratory disorders.
  • Investigator Discretion: Other conditions deemed by the investigator to contraindicate participation.

Other

  • Refusal of Novel Technique: Patients unwilling to undergo intraoperative thoracic duct ligation.

Who the study is looking for

  • Age \& Gender: Individuals aged 18-75 years, regardless of gender.
  • Clinical Profile:Diagnosed with early-stage lung cancer (stage IA1-IB) and obesity (BMI ≥28 kg/m²).
  • Scheduled to undergo video-assisted thoracoscopic surgery (VATS) for right-sided lung cancer resection at our institution between October 2024 and October 2026.
  • Surgical Eligibility: Approved for surgery following multidisciplinary team (MDT) assessment.
  • Treatment Plan: No requirement for adjuvant therapy post-lung resection.
  • Preoperative Evaluation:Completed standard preoperative workup, including:
  • Chest CT、Brain CT/MRI、Abdominal ultrasound OR PET-CT to rule out distant metastasis.
  • Informed Consent: Willing and able to comply with study requirements, with written informed consent provided.

Age in the registry: 18 days to 75 days · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.